Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External validation of prognostic multivariable risk models for surgical site infections after open lower extremity revascularization for peripheral arterial disease.

Surgery·2026
Same author

ASO Visual Abstract: Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients.

Annals of surgical oncology·2025
Same author

Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients.

Annals of surgical oncology·2025
Same author

Carotid Interventions in the Community are Associated with Higher Rates of Complications.

Annals of vascular surgery·2025
Same author

Mechanical thrombectomy of inferior vena cava filter-associated caval thrombosis using FlowTriever and ClotTriever systems.

Journal of vascular surgery. Venous and lymphatic disorders·2023
Same author

Factors associated with preference of choice of aortic aneurysm repair in the PReference for Open Versus Endovascular repair of AAA (PROVE-AAA) study.

Journal of vascular surgery·2022
Same journal

Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Norepinephrine Versus Dopamine as Vasoactive Therapy in Cardiogenic Shock: Association With 28-Day Mortality in a Retrospective Cohort Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Alterations of Platelet MicroRNAs Associated With Dapagliflozin Treatment in Individuals With Type 2 Diabetes Mellitus.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Comparative Effectiveness of Renin-Angiotensin System Inhibitors in Heart Failure With Nonreduced Ejection Fraction: A Multicenter Cohort Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Shared Genetic Liability Between Heart Failure and Myocardial Infarction Revealed by Genome-Wide Cross-Trait Analysis.

Journal of cardiovascular pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Direct thrombin inhibitors.

P Joshua O'Brien1, Leila Mureebe

  • 1Department of Surgery, Section of Vascular Surgery, Duke University Medical Center, Durham, NC 27710, USA. josh.obrien@duke.edu

Journal of Cardiovascular Pharmacology and Therapeutics
|February 22, 2011
PubMed
Summary
This summary is machine-generated.

Direct thrombin inhibitors offer a more specific approach to anticoagulation for cardiovascular disease, addressing limitations of older drugs. This review covers their mechanisms, uses, and future clinical trials.

More Related Videos

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
06:16

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Published on: April 19, 2024

Related Experiment Videos

Last Updated: Jun 4, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
06:16

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Published on: April 19, 2024

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Cardiovascular disease is a major cause of mortality globally.
  • Pathologic coagulation is central to cardiovascular disease progression and treatment.
  • Current anticoagulants like heparin and vitamin K antagonists have drawbacks.

Purpose of the Study:

  • To review direct thrombin inhibitors (DTIs).
  • To discuss current clinical indications for DTIs.
  • To explore ongoing clinical trials involving DTIs.

Main Methods:

  • Review of scientific literature on direct thrombin inhibitors.
  • Analysis of clinical trial data and guidelines.

Main Results:

  • Thrombin plays a critical role in coagulation.
  • DTIs target thrombin directly, offering specificity.
  • Various DTIs are approved or in development.

Conclusions:

  • Direct thrombin inhibitors represent an advancement in anticoagulation therapy.
  • DTIs offer improved specificity over traditional anticoagulants.
  • Ongoing trials will further define the role of DTIs in cardiovascular disease management.